Neoplastic effect of indomethacin in N-methyl-N-nitrosourea induced mammary carcinogenesis in female rats;Neoplastické účinky indometacínu v N-metyl-N-nitrozoureou indukovanej mamárnej karcinogenéze u samíc potkanov

Klinicka Onkologie

Volumn 25, Issue 5, 2012, Pages 359-363

  Kubatka, Peter ^a   Kalicka K ^b   Bojkova B ^b   Ahlers, I ^b   Ahlersova E ^b   Pec M ^a  

^a Physics and Informatics   (Slovakia)

^b P J AFÁRIK UNIVERSITY   (Slovakia)

Author keywords

Chemoprevention; Indomethacin; Mammary carcinogenesis; Melatonin; Rats

Indexed keywords

INDOMETACIN; MELATONIN; METHYLNITROSOUREA;

ANIMAL EXPERIMENT; ARTICLE; BREAST CARCINOGENESIS; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; NONHUMAN; RAT; TREATMENT DURATION; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; ANTICARCINOGENIC AGENTS; CHEMOPREVENTION; FEMALE; INDOMETHACIN; MAMMARY NEOPLASMS, EXPERIMENTAL; MELATONIN; METHYLNITROSOUREA; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84868339360     PISSN: 0862495X     EISSN: 18025307     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Cuzick J, Otto F, Baron JA et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 2009; 10(5): 501-507.
2. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 2000; 30(1): 3-21. (Pubitemid 30078300)
3. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325(23): 1593-1596.
4. Harris RE, Kasbari S, Farrar WB. Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol Rep 1999, 6(1): 71-73.
5. Nelson JE, Harris RE. Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study Oncol Rep 2000; 7(1): 169-170.
6. Harris RE, Beebe-Donk J, Schuller HM. Chemoprevention of lung cancer by non-steroidal anti-inflammatory drugs among cigarette smokers. Oncol Rep 2002; 9(4): 693-695.
7. Cotterchio M, Kreiger N, Sloan M et al. Nonsteroidal anti-inflammatory drug use and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2001; 10(11): 1213-1217. (Pubitemid 33064311)
8. Jang TJ, Jung HG, Jung KH, O MK. Chemopreventive effect of celecoxib and expression of cyclooxygenase-1and cyclooxygenase-2 on chemically-induced rat mammary tumours. Int J Exp Pathol 2002; 83(4): 173-182. (Pubitemid 36004149)
9. Suzui N, Sugie S, Rahman KM et al. Inhibitory effects of diallyl disulfide or aspirin on 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyzridine-induced mammary carcinogenesis in rats. Jpn J Cancer Res 1997; 88(8): 705-711. (Pubitemid 27404013)
10. Mocikova-Kalicka K, Bojkova B, Adamekova E et al. Preventive effect of indomethacin and melatonin on 7,12-dimethybenz/a/anthracene-induced mammary carcinogenesis in female Sprague-Dawley rats. A preliminary report. Folia Biol (Praha) 2001; 47(2): 75-79. (Pubitemid 32266555)
11. Kubatka P, Kalicka K, Chamilova M et al. Nimesulide and melatonin in mammary carcinogenesis prevention in female Sprague-Dawley rats. Neoplasma 2002; 49(4): 255-259.
12. Kubatka P, Ahlers I, Ahlersová E et al. Chemoprevention of mammary carcinogenesis in female rats by rofecoxib. Cancer Lett 2003; 202(2): 131-136. (Pubitemid 37485885)
13. Orendas P, Ahlers I, Kubatka P et al. Etoricoxib in the prevention of rat mammary carcinogenesis. Acta Vet (Brno) 2007; 76(4): 613-618. (Pubitemid 351569943)
14. Orendas P, Kassayova M, Kajo K et al. Celecoxib and melatonin in prevention of female rat mammary carcinogenesis. Neoplasma 2009; 56(3): 250-256.
15. Harris RE, Alshafie GA, Abou-Issa H et al. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 2000; 60(8): 2101-2103. (Pubitemid 30225166)
16. Kawamori T, Rao CV, Seibert K et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998; 58(3): 409-412. (Pubitemid 28087398)
17. Grubbs CJ, Lubet RA, Koki AT et al. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 2000; 60(20): 5599-5602.
18. Cos S, González A, Martínez-Campa C et al. Melatonin as a selective estrogen enzyme modulator. Curr Cancer Drug Targets 2008; 8(8): 691-702.
19. Hamid R, Singh J, Reddy BS et al. Inhibition by dietary menhaden oil of cyclooxygenase-1 and 2 in N-nitro-somethylurea-induced rat mammary tumors. Int J Oncol 1999; 14(3): 523-528.
20. McCormick DL, Madigan MJ, Moon RC. Modulation of rat mammary carcinogenesis by indomethacin. Cancer Res 1985; 45(4): 1803-1808. (Pubitemid 15079141)
21. Noguchi M, Taniya T, Koyasaki N et al. Effects of the prostaglandin synthetase inhibitor indomethacin on tumorigenesis, tumor proliferation, cell kinetics, and receptors contents of 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in Sprague-Dawley rats fed a high- or low-fat diet. Cancer Res 1991; 51(10): 2683-2689.
22. Noguchi M, Ohta N. Influences of high dietary fat and/or indomethacin on tumor proliferation and cell kinetics of 7,12-dimethylbenz(a)anthracene-induced mammary carcinomas in rats. In Vivo 1993; 7(1): 53-58.
23. Noguchi M, Erashi M, Miyazaki I et al. Effects of indomethacin with or without linoleic acid on human breast cancer cells in vitro. Prostaglandins Leukotr Essent Fatty Acids 1995; 52(6): 381-386.
24. McCormick DL, Moon RC. Indomethacin inhibits mammary carcinogenesis in rats. Proc Int Assoc Breast Cancer Res 1983; 1: 43.
25. Kohl S, Jansen DM, Loo LS. Indomethacin enhancement of human natural killer cytotoxicity to herpes simplex virus infected cells in vitro and in vivo. Prostaglandins Leukot Med 1982; 9(2): 159-166. (Pubitemid 12042894)
26. Shimamura T, Hashimoto K, Sasaki S. Feedback suppression of the immune response in vivo. I. Immune B cells induce antigen-specific suppressor T cells. Cell Immunol 1982; 68(1): 104-113. (Pubitemid 12105292)
27. Gołab J, Kozar K, Kamiński R et al. Interleukin 12 and indomethacin exert a synergistic angiogenesis-dependent antitumor activity in mice. Life Sci 2000; 66(13): 1223-1230. (Pubitemid 30112471)
28. Nakatsugi S, Ohta T, Kawamori T et al. Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-methyl-phenylimidazo[4,5-b] pyridine (PhIP)-induced mammary gland carcinogenesis in rats. Jpn J Cancer Res 2000; 91(9): 886-892.
29. Howard PA, Delafontaine P. Nonsteroidal anti-inflammatory drugs and cardiovascular risk. J Am Coll Cardiol 2004; 43(4): 519-525. (Pubitemid 38229519)
30. Kearney PM, Baigent C, Godwin J et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332(7553): 1302-1308.
31. Harris RE, Beebe-Donk J, Doss H et al. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade. Oncol Rep 2005; 13(4): 559-583.
32. Harris RE. Cyclooxygenase-2 /COX-2/ and the inflammogenesis of cancer. In: Harris RE (ed). Inflammation in the Pathogenesis of Chronic Diseases. New York: Springer 2007: 93-126.
33. Agrawal A, Fentiman IS. NSAIDs and breast cancer: a possible prevention and treatment strategy. Clin Pract 2008; 62(3): 444-449. (Pubitemid 351197419)
34. Takkouche B, Regueira-Méndez C, Etminan M. Breast cancer and use of non-steroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst 2008; 100(2): 1439-1447.
35. Harris RE, Beebe-Donk J, Alshafie GA. Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 2006; 6: 27.